Brief Title: A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Incidence of Treatment Emergent Adverse Events (TEAEs) estimated during the Adverse Events (AE) evaluation

Primary Outcome 1 - Timeframe: Start of treatment up to 30 days after last dose or start of new anticancer therapy (whichever occurs first)

Primary Outcome 2 - Measure: Part 1: Number of Participants With Dose-limiting Toxicities (DLTs): Monotherapy

Primary Outcome 2 - Timeframe: Baseline to end of DLT evaluation period

Primary Outcome 3 - Measure: Part 1: Recommended Monotherapy Dose for Expansion

Primary Outcome 3 - Timeframe: Baseline to 30 days post last study drug administration

Primary Outcome 4 - Measure: Part 2: Recommended Phase 2 Dose

Primary Outcome 4 - Timeframe: Baseline to 30 days post last study drug administration

CONDITION

• Advanced/Metastatic Solid Tumors
• Bladder Cancer
• Urothelial Carcinoma
• Advanced Non-Small Cell Lung Cancer
• Carcinoma
• Non Small Cell Lung
• Carcinoma
• Squamous Cell of Head and Neck
• Head and Neck Cancer
• Esophageal Cancer
• Gastroesophageal Junction Adenocarcinoma
• Esophageal Squamous Cell Carcinoma
• Esophageal Adenocarcinoma
• Pancreatic Adenocarcinoma
• Pancreatic Cancer

ELIGIBILITY

Inclusion Criteria:
* 18 years of age or older

- * Advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas

- * Measurable disease

- * ECOG Performance status 0-1

- * Part 1: progression or relapse following standard treatments

- * Part 2: maximum of 2 prior lines of systemic therapy in the advanced setting

- * Resolution of acute effects of prior anticancer therapy to baseline or Grade 1

- * Consent to submit required pre-treatment tumor tissue as medically feasible
Exclusion criteria:
* Received prior treatment with an antibody drug conjugate with a camptothecin-class payload (e.g. sacituzumab govitecan, trastuzumab deruxtecan )

- * Active anorexia, nausea or vomiting, and/or signs of intestinal obstruction meeting protocol exclusion

- * Pulmonary disease meeting protocol exclusion

- * Other unacceptable abnormalities as defined by protocol

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Pfizer CT.gov Call Center

Role: Study Director

Affiliation: Pfizer

Overall Contact

Name: Pfizer CT.gov Call Center

Phone: 1-800-718-1021

Email: [email protected]

LOCATION